The Journal of clinical endocrinology and metabolism
-
Bisphosphonates have been widely used in the treatment of osteoporosis. Uncommon side effects have emerged in postapproval use. Because bisphosphonates accumulate in bone and are released for months or years after treatment is stopped, it is reasonable to consider the clinical question of how long to treat. ⋯ Bisphosphonates are popular and effective for treatment of osteoporosis. Because they accumulate in bone and provide some residual antifracture reduction when treatment is stopped, we recommend a drug holiday after 5-10 yr of bisphosphonate treatment. The duration of treatment and length of the holiday are based on fracture risk and pharmacokinetics of the bisphosphonate used. Patients at mild risk might stop treatment after 5 yr and remain off as long as bone mineral density is stable and no fractures occur. Higher risk patients should be treated for 10 yr, have a holiday of no more than a year or two, and perhaps be on a nonbisphosphonate treatment during that time.
-
J. Clin. Endocrinol. Metab. · Apr 2010
Randomized Controlled TrialEffects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Teriparatide increases both bone formation and bone resorption. ⋯ Alendronate reduces the ability of teriparatide to increase BMD and bone turnover in women.
-
J. Clin. Endocrinol. Metab. · Apr 2010
Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer.
Overexpression of IGF-II and IGF-binding protein (IGFBP)-2 has been reported in several cancers. ⋯ IGFBP-2 is a potential diagnostic and prognostic biomarker of CRC. LOI of IGF-II is significantly associated with poor prognosis in patients with stage IV disease.